Xbrane Biopharma and Biogen have struck a global licensing and commercialization deal for Xbrane’s Xcimzane (certolizumab pegol) proposed biosimilar rival to Cimzia that is currently at the pre-clinical stage. Through the agreement, Biogen will gain exclusive global regulatory, manufacturing and commercial rights to Xcimzane and will be the marketing authorization holder for the biosimilar.
Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar
Xbrane CEO Martin Åmark Highlights Potential For Xcimzane Rival To Cimzia
Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.